Oregon Drug Use Review /Pharmacy & Therapeutics Committee
Thursday, March 29, 2012 1:00-4:00 PM
Hewlett-Packard Building
4070 27th Ct SE
Salem, OR 97302

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to coverage, PDL composition, or utilization control recommendations to the OHA.

Members Present: Tracy Klein, PhD, FNP; William Origer, MD; Stacy Ramirez, PharmD; Zahia Esber, MD
Members Present by Phone: Andris Antoniskis, MD; Joshua Bishop, PharmD; Phillip Levine, PhD
Staff Present: Roger Citron, RPh; Megan Herink, PharmD, BCPS; Kathy Ketchum, RPh, MPA;HA; Valerie Smith; Richard Holsapple, RPh; Ralph Magrish, MPA; Ann Hamer, PharmD; Bing-Bing Liang, PharmD;
Staff Present by Phone: Brandy Fouts, PharmD
Audience Present: Jim Graves (BMS); Jeff Forshey (Shire); Ben Davidson (Physician); Deron Grothe (Teva); Deborah Crawford (Acorda); Lauren Letzenberger (Janssen Scientific Affairs); Craig Black (Biogen Idec); Jeanacolabianchi (Sunovion); Lyle Laird (Sunovion); Paul Sparks; Kimberly Langmeier (BMS); Lori Howarth (Bayer); Bruce Howard (Acorda); Rosalynde Finch (Biogen Idec); Kathy Kirk (OPMC); Elaine Thomas (Bayer); Don Stetcher (Novartis); John Brokars; Mary Kemhus; Denise Poole; Rob Pearson; Deborah Wafe; Diann Matthews; Angela Hamman; Paul Nielsen; James Matthucci; Amy Tice; Canan Shumann

I. CALL TO ORDER
   a. The meeting was called to order at approximately 1:20pm
   b. Conflict of interest declarations were reviewed and no new conflicts were reported
   c. The February 23, 2012 meeting minutes were reviewed.

   ACTION: Approved as is.

II. OLD BUSINESS
   a. Hepatitis C criteria were brought back with the addition of steps 5-9 after consulting with a Hepatologist.

   *ACTION: Approved as amended from the last meeting.

   b. Dose optimization concept was presented by Mr. Citron.

   ACTION: Approved as amended to remove drugs that required titration (e.g. hypertension drugs, lamotrigine, quetiapine). Staff directed to identify drugs to target for this policy based upon past claim data.

III. NEW BUSINESS
   a. Dr. Williams presented on Short Acting Opioids and recommended using the same criteria for Short Acting Opioids as Long Acting Opioids.

   *ACTION: Approved as is after Executive Session. Staff directed to implement with educational component and adequate notice to providers. Also recommended butorphanol NS non-preferred, oxycodone 5mg capsule non-preferred, oxycodone concentrate non-preferred, oxycodone 2.5mg/APAP non-preferred, Conzip® non-preferred.
b. Dr. Herink presented on Multiple Sclerosis drug class including new drug reviews for fingolimod and dalfampridine. It was recommended that fingolimod be made non-preferred with a trial of interferon first. Dalfampridine was recommended to be managed with prior authorization criteria and it was referred to HERC for cost-effectiveness evaluation in comparison to non-pharmacological treatments. Dr. Ben Davidson presented public comment on MS drug class in general. Elaine Thomas from Bayer presented public comment on Betaseron®. Rosalynde Finch from Biogen Idec presented public comment on Avonex®. Mary Kenhus from Novartis presented public comment on Gilenya®. Deborah Crawford from Acorda presented public comment on Ampyra®.

*ACTION: Approved as presented after Executive Session.

c. Dr. Hamer presented on Antipsychotic drug class recommending education outreach to promote appropriate utilization and minimize inappropriate off-label use and making lurasidone non-preferred. Lyle Laird from Sunvion presented public comment on Latuda®. Written testimony was provided by Dr. Lisa Boy on Latuda®. Mary Kemhus from Novartis presented public comment on Fanapt®.

*ACTION: Approved as presented after Executive Session. It was also recommended to review class pricing again in three months and to have staff to present a specific educational proposal.

d. Dr. Liang presented the Statin drug class update recommending that quantity limits be implemented on 80mg simvastatin, and making pitavastatin non-preferred.

*ACTION: Approved as presented after Executive Session and recommended revisiting pricing in three months.

e. Dr. Fouts presented the new drug evaluation and recommended implementing dose limits, age restrictions, and diagnosis documentation on icatibant.

*ACTION: Committee deferred action and asked staff for more information regarding current utilization of this class and icatibant’s place in therapy.

f. Dr. Williams presented the ADHD drug class update recommending not considering extended release forms of clonidine and guanfacine superior to other stimulant and non-stimulant ADHD treatments for PDL placement. John Brokers from Eli Lilly presented public comment on Stratera.

*ACTION: After Executive Session it was recommended Kapvay®, Daytrana®, generic methamphetamine and Concerta® and its generic equivalent be made non-preferred. It was recommended Intuniv® be listed preferred after successful contract negotiations.

g. Dr. Herink presented drug class scans.

1. Sedative Hypnotics – recommend no further research or review at this time. Make Silenor® and Edular® non-preferred.
2. Skeletal Muscle Relaxants – recommend no further research or review at this time.
3. Triptans – recommend no further research or review at this time.

*ACTION: After executive session the Sedative Hypnotic recommendations were approved and it was recommended to make all Skeletal Muscle Relaxant agents non-preferred except baclofen, cyclobenzaprine and tizanidine.

IV. EXECUTIVE SESSION

V. RECONVENE for PUBLIC RECOMMENDATIONS*

VI. The meeting adjourned at 4:45pm.